DNALite Therapeutics

About:

DNALite Therapeutics is an early-stage preclinical biotechnology company.

Twitter/X: DNALiteTx

Top Investors: IndieBio, National Science Foundation, SOSV, BrightGene, CITRIS Foundry

Description:

DNALite Therapeutics is an early-stage preclinical biotechnology company committed to bringing the next generation of drugs to the gastrointestinal tract. It develops oral lipid nanoparticle technology to deliver mRNA and pDNA into the intestine using the oral route of administration. Its drug aims to use the intestinal tract to secrete proteins into the bloodstream turning any protein biologic into an oral drug.

Total Funding Amount:

$8.29M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2016-01-01

Founders:

Mubhij Ahmad, Timothy Day

Number of Employees:

1-10

Last Funding Date:

2023-03-07

IPO Status:

Private

Industries: